Johnson & Johnson (NYSE:JNJ – Get Free Report) has earned a consensus recommendation of “Hold” from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $169.19.
A number of research analysts recently commented on the company. Wells Fargo & Company reduced their price target on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a report on Thursday, August 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Friday. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 18th. HSBC started coverage on shares of Johnson & Johnson in a research report on Wednesday, September 6th. They set a “hold” rating and a $175.00 price target on the stock. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 26th.
Institutional Trading of Johnson & Johnson
Johnson & Johnson Price Performance
Shares of JNJ stock opened at $149.91 on Tuesday. The company has a market capitalization of $360.88 billion, a PE ratio of 11.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58. The firm has a fifty day simple moving average of $154.52 and a 200-day simple moving average of $160.29. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $181.04.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. The company had revenue of $21.35 billion during the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. Equities research analysts anticipate that Johnson & Johnson will post 10.1 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be paid a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Monday, November 20th. Johnson & Johnson’s payout ratio is 35.34%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- What Are Dividend Challengers?
- Safeguard your portfolio with these three bargain stocks
- Health Care Stocks Explained: Why You Might Want to Invest
- Membership clubs gain leverage for the consumer rebound
- How to Invest in Electric Cars
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.